Skip to main content
. Author manuscript; available in PMC: 2017 Sep 11.
Published in final edited form as: Am J Hematol. 2009 Jun;84(6):366–370. doi: 10.1002/ajh.21405

Figure 1.

Figure 1

Initial clinical evaluation strategy to determine which patients would benefit most from further diagnostic evaluation for von Willebrand disease (VWD) or other bleeding disorders. Individuals (for example, an asymptomatic person who will undergo a surgical or other invasive procedure) would be asked three questions (left upper box), which, if any responses are positive, would lead to a second set of nine questions selected for sensitivity and specificity for VWD (Box 1, lower right). Individuals presenting with specific information or a concern about bleeding would be asked the Box 1 questions and the initial three questions if not already asked, and would also undergo laboratory evaluation. DDAVP, desmopressin; NSAIDs, nonsteroidal anti-inflammatory drugs. Modified from Ref. 2, Fig. 1.